CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple
Geographies Against Pfizer/BioNTech

Issuer: CureVac / Key word(s): Patent
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple
Geographies Against Pfizer/BioNTech

11.07.2024 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple
Geographies Against Pfizer/BioNTech

  * New trial date for U.S. patent litigation set for March 3, 2025,
    following settlement with Acuitas Therapeutics

  * First instance decision on validity of EP 3 708 668 B1 (split poly-A
    tail technology) scheduled for March 25, 2025, by European Patent Office
    in the context of the German patent litigation

  * UK trial on validity of intellectual property rights EP 3 708 668 B1 and
    EP 4 023 755 B1 (split poly-A tail technology) began July 10; judgement
    expected later in 2024

TÜBINGEN, Germany/BOSTON, USA - July 11, 2024 - CureVac N.V. (Nasdaq: CVAC)
('CureVac'), a global biopharmaceutical company developing a new class of
transformative medicines based on messenger ribonucleic acid ('mRNA'), today
announced the latest trial dates for its ongoing patent litigation against
Pfizer/BioNTech in multiple geographies including the U.S., UK and Germany.

The U.S. trial against Pfizer/BioNTech will take place on March 3, 2025,
before the U.S. District Court of the Eastern District of Virginia. A
previously issued court recommendation to stay the proceedings for all 10
U.S. patents was withdrawn. The recommendation had followed a motion by
Acuitas Therapeutics to intervene, sever and stay proceedings based on
co-owner and co-inventorship claims. It was resolved after both companies
reached a settlement in April 2024, which provided Acuitas licenses to
several patents, including three out of four disputed U.S. patents. These
three patents have been withdrawn from the U.S. patent litigation against
Pfizer/BioNTech. In return, Acuitas acknowledges that CureVac is the sole
owner of the disputed patents.

Litigation in Europe will continue March 25, 2025, with a hearing on the
validity of EP 3 708 668 B1 (split poly-A tail technology), before the
Opposition Division of the European Patent Office. The infringement action
in relation to this patent was previously suspended pending the validity
determination by the European Patent Office. In the German patent litigation
against Pfizer/BioNTech, the settlement with Acuitas Therapeutics led to the
withdrawal of two utility models covering equivalent claims to the three
patents withdrawn in the United States. As previously announced, a hearing
before the infringement court of Düsseldorf covering the European patent EP
4 023 755 B1 (split poly-A tail technology) and the utility model DE 20 2021
004 130 U1 (COVID-19 vaccine design), is scheduled for September 10, 2024.

Furthermore, a trial in the UK has started on July 10, 2024. It is based on
a declaration of non-infringement and request for revocation by
Pfizer/BioNTech in the UK for the two CureVac patents EP 3 708 668 B1 and EP
4 023 755 B1 (split poly-A-tail technology). CureVac counterclaimed for
infringement. A judgement is expected later in 2024. The trial for the
further involved patent EP 1 857 122 B1 (G/C enrichment technology) will be
set for a later time point.


About CureVac
CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded
in 2000 to advance the field of messenger RNA (mRNA) technology for
application in human medicine. In more than two decades of developing,
optimizing, and manufacturing this versatile biological molecule for medical
purposes, CureVac has introduced and refined key underlying technologies
that were essential to the production of mRNA vaccines against COVID-19, and
is currently laying the groundwork for application of mRNA in new
therapeutic areas of major unmet need. CureVac is leveraging mRNA
technology, combined with advanced omics and computational tools, to design
and develop off-the-shelf and personalized cancer vaccine product
candidates. It also develops programs in prophylactic vaccines and in
treatments that enable the human body to produce its own therapeutic
proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in
the Netherlands, Belgium, Switzerland, and the U.S. Further information can
be found at www.curevac.com.


CureVac Media Contact
Patrick Perez, Junior Manager Public Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1831
M: +49 151 14 115247
patrick.perez@curevac.com


CureVac Investor Relations Contact
Dr. Sarah Fakih, Vice President Corporate Communications and Investor
Relations
CureVac, Tübingen, Germany
T: +49 7071 9883-1298
M: +49 160 90 496949
sarah.fakih@curevac.com


Forward-Looking Statements CureVac
This press release contains statements that constitute 'forward looking
statements' as that term is defined in the United States Private Securities
Litigation Reform Act of 1995, including statements that express the
opinions, expectations, beliefs, plans, objectives, assumptions or
projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE,
CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac
Corporate Services GmbH, CureVac RNA Printer GmbH, CureVac Belgium SA and
CureVac Netherlands B.V. (the 'company') regarding future events or future
results, in contrast with statements that reflect historical facts. Examples
include discussion of the potential efficacy of the company's vaccine and
treatment candidates and the company's strategies, financing plans, cash
runway, growth opportunities and market growth. In some cases, you can
identify such forward-looking statements by terminology such as
'anticipate,' 'intend,' 'believe,' 'estimate,' 'plan,' 'seek,' 'project,' or
'expect,' 'may,' 'will,' 'would,' 'could,' 'potential,' 'intend,' or
'should,' the negative of these terms or similar expressions.
Forward-looking statements are based on management's current beliefs and
assumptions and on information currently available to the company. However,
these forward-looking statements are not a guarantee of the company's
performance, and you should not place undue reliance on such statements.
Forward-looking statements are subject to many risks, uncertainties and
other variable circumstances, including negative worldwide economic
conditions and ongoing instability and volatility in the worldwide financial
markets, ability to obtain funding, ability to conduct current and future
preclinical studies and clinical trials, the timing, expense and uncertainty
of regulatory approval, reliance on third parties and collaboration
partners, ability to commercialize products, ability to manufacture any
products, possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition and
consolidation in the company's industry, the effects of the COVID-19
pandemic on the company's business and results of operations, ability to
manage growth, reliance on key personnel, reliance on intellectual property
protection, ability to provide for patient safety, fluctuations of operating
results due to the effect of exchange rates, delays in litigation
proceedings, different judicial outcomes or other factors. Such risks and
uncertainties may cause the statements to be inaccurate and readers are
cautioned not to place undue reliance on such statements. Many of these
risks are outside of the company's control and could cause its actual
results to differ materially from those it thought would occur. The
forward-looking statements included in this press release are made only as
of the date hereof. The company does not undertake, and specifically
declines, any obligation to update any such statements or to publicly
announce the results of any revisions to any such statements to reflect
future events or developments, except as required by law.

For further information, please reference the company's reports and
documents filed with the U.S. Securities and Exchange Commission (SEC). You
may get these documents by visiting EDGAR on the SEC website at www.sec.gov.


---------------------------------------------------------------------------

Dissemination of a Corporate News, transmitted by EQS News - a service of
EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        CureVac
                   Friedrich-Miescher-Str. 15
                   72076 Tübingen
                   Germany
   EQS News ID:    1944401

End of News EQS News Service
---------------------------------------------------------------------------